US Patent Issued to Hackensack Meridian Health Center for Discovery and Innovation on Oct. 20 for "Methods for use of an angiocrine factor in treating a patient exposed to a myeloablative insult" (New Jersey Inventor)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,766,185, issued on Oct. 20, was assigned to Hackensack Meridian Health Center for Discovery and Innovation (Nutley, N.J.).

"Methods for use of an angiocrine factor in treating a patient exposed to a myeloablative insult" was invented by Jason M. Butler (Nutley, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The described invention identifies endothelial cells within the perivascular niche as a crucial component in driving bone marrow (BM) inflammation and HSC dysfunction. We demonstrate that crosstalk between ERK-MAPK and NF-KappaB signaling pathways within the endothelium plays a key role in modulating the outcomes of chronic inflammation. Sustain...